| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/21/2010 | WO2010007168A2 Treatment of rheumatoid arthritis with mammal beta defensins |
| 01/21/2010 | WO2010007166A2 Treatment of inflammatory bowel diseases with mammal beta defensins |
| 01/21/2010 | WO2010007165A2 Treatment of inflammatory diseases with mammal beta defensins |
| 01/21/2010 | WO2010007147A1 Anticancer compounds |
| 01/21/2010 | WO2010007144A2 New mutated netrin 4 proteins, fragments thereof and their uses as drugs |
| 01/21/2010 | WO2010007085A2 Use of organic compounds |
| 01/21/2010 | WO2010006809A2 Medical use of the radical scavenger and antioxidant alpha-1-microglobulin |
| 01/21/2010 | WO2010006808A1 Composition comprising in vitro expanded t-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer |
| 01/21/2010 | WO2010006720A1 Anti-amyloid immunogenic compositions, methods and uses |
| 01/21/2010 | WO2010006682A1 Method for producing intermediates for the production of novel macrocycles that are inhibitors of the proteasomic degradation of p27, such as argyrin and derivatives thereof, and uses of said macrocycles |
| 01/21/2010 | WO2010006635A1 Treatment of inflammatory bowel disease |
| 01/21/2010 | WO2010006634A1 Prevention and treatment of radiation injury |
| 01/21/2010 | WO2010006508A1 INTEGRIN PEPTIDE, ANTI-CD 18 βA ANTIBODY FOR TREATMENT OF ENDOTOXIN-MEDIATED PRO-INFLAMMATORY RESPONSES AND THE USE |
| 01/21/2010 | WO2010006501A1 Annexin ii compositions for treating or monitoring inflammation or immune-mediated disorders field of the invention |
| 01/21/2010 | WO2010006476A1 Myocardial peptide, preparation method and uses thereof |
| 01/21/2010 | WO2010006377A1 Therapeutic agents |
| 01/21/2010 | WO2009149393A3 Improved cancer drug delivery using modified transferrin |
| 01/21/2010 | WO2009149279A3 Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| 01/21/2010 | WO2009145489A3 Cell-permeable endostatin recombinant protein, a polynucleotide coated with the same, and an anti-cancer preparation containing the same as an active component |
| 01/21/2010 | WO2009137605A3 AFFINITY MATURED CRIg VARIANTS |
| 01/21/2010 | WO2009134967A3 Use of nucleic acids with reduced pressure therapy for treating wounds |
| 01/21/2010 | WO2009132129A3 Isoform-specific insulin analogues |
| 01/21/2010 | WO2009129374A3 Methods and compositions for preventing adhesion |
| 01/21/2010 | WO2009129220A3 Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma |
| 01/21/2010 | WO2009128936A3 Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants |
| 01/21/2010 | WO2009117710A3 Methods of treating inflammation |
| 01/21/2010 | WO2009117127A3 Nerve repair with a hydrogel and optional adhesive |
| 01/21/2010 | WO2009117116A3 Heat shock protein gp96 vaccination and methods of using same |
| 01/21/2010 | WO2009112583A3 Protease-stabilized insulin analogues |
| 01/21/2010 | WO2009104911A4 Uses as agents for prophylaxis or treatment of cervical cancer |
| 01/21/2010 | WO2009103319A3 Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for treating or detecting streptococcal diseases |
| 01/21/2010 | WO2009067636A3 Modified insulin polypeptides and their uses |
| 01/21/2010 | WO2009061447A3 Use of umbilical cord blood in the treatment of premature birth complications |
| 01/21/2010 | WO2009056569A9 Lh liquid formulations |
| 01/21/2010 | WO2009045412A3 Methods of treatment using modified plasminogen activator inhibitor type-1 molecules |
| 01/21/2010 | WO2009023306A3 Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens |
| 01/21/2010 | WO2005074521A9 C-TERMINAL p53 PALINDROMIC PEPTIDE THAT INDUCES APOPTOSIS OF CELLS WITH ABERRANT p53 AND USES THEREOF |
| 01/21/2010 | WO2004058153A9 Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476. |
| 01/21/2010 | WO2004041170A9 Compositions and methods for the treatment of immune related diseases |
| 01/21/2010 | WO2004039333A9 ANTIGENIC gp 100 COMPOUNDS FOR THERAPY AND DIAGNOSIS AND METHODS FOR USING SAME |
| 01/21/2010 | WO2004024097A9 Compositions and methods for the treatment of immune related diseases |
| 01/21/2010 | WO2003006609A9 Human cytokine receptor |
| 01/21/2010 | US20100017901 Compositions Comprising MG29 Nucleic Acids, Polypeptides, and Associated Methods of Use |
| 01/21/2010 | US20100017896 Filaggrin |
| 01/21/2010 | US20100017895 Small animal model for hcv replication |
| 01/21/2010 | US20100016938 Diagnosing, monitoring and treating inflammation |
| 01/21/2010 | US20100016562 Reducing the immunogenicity of fusion proteins |
| 01/21/2010 | US20100016561 N-Acetylglucosaminyltransferase III Expression in Lower Eukaryotes |
| 01/21/2010 | US20100016558 Cloning and recombinant production of receptor(s) of the activin/tgf-beta superfamily |
| 01/21/2010 | US20100016557 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha |
| 01/21/2010 | US20100016556 Method for making humanized antibodies |
| 01/21/2010 | US20100016555 N-Acetylglucosaminyltransferase III Expression in Lower Eukaryotes |
| 01/21/2010 | US20100016552 Novel hemopoietic receptor protein, NR10 |
| 01/21/2010 | US20100016549 Peyer's patch and/or m-cell targeting ligands |
| 01/21/2010 | US20100016415 Proteins Expressed by Mycobacterium Tuberculosis and not by BCG and their use as Diagnostic Reagents and Vaccines |
| 01/21/2010 | US20100016254 Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
| 01/21/2010 | US20100016243 Crystalline d-isoglutamyl-d-tryptophan and the mono ammonium salt of d-isoglutamyl-d-tryptophan |
| 01/21/2010 | US20100016242 Myosin light chain kinase inhibitors and methods of use |
| 01/21/2010 | US20100016241 Methods and compositions for inhibiting c-met dimerization and activation |
| 01/21/2010 | US20100016240 Facilitating cells and diabetes and methods related thereto |
| 01/21/2010 | US20100016239 Heparin binding motif and use thereof |
| 01/21/2010 | US20100016238 Peptides for Use in the Treatment of Obesity |
| 01/21/2010 | US20100016237 Novel Peptides for Use in the Treatment of Obesity |
| 01/21/2010 | US20100016236 Osteogenic synthetic peptides, pharmaceutical compositions comprising the same, and medium containing the same |
| 01/21/2010 | US20100016235 Inhibitors of Protein Phosphatase 1, GADD34 and Protein Phosphatase 1/GADD34 Complex, Preparation and Uses Thereof |
| 01/21/2010 | US20100016234 Signal peptides, nucleic acid molecules and methods for treatment of caries |
| 01/21/2010 | US20100016233 Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues |
| 01/21/2010 | US20100016232 Treatment Of Inflammatory Diseases With Mammal Beta Defensins |
| 01/21/2010 | US20100016231 Treatment Of Rheumatoid Arthritis With Mammal Beta Defensins |
| 01/21/2010 | US20100016230 Treatment Of Inflammatory Bowel Diseases With Mammal Beta Defensins |
| 01/21/2010 | US20100016229 Oral GLP-1 Formulations |
| 01/21/2010 | US20100016228 Truncated bard1 protein, and its diagnostic and therapeutic uses |
| 01/21/2010 | US20100016227 Ligand/lytic peptide compositions and methods of use |
| 01/21/2010 | US20100016226 Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease |
| 01/21/2010 | US20100016225 CONJUGATES COMPRISED OF POLYMER AND HIV gp-41-DERIVED PEPTIDES AND THEIR USE IN THERAPY |
| 01/21/2010 | US20100016224 Compositions and methods for modulating an immune response |
| 01/21/2010 | US20100016223 Treatment of cartilage disorders with fgf-18 |
| 01/21/2010 | US20100016222 Novel agent for inducing apoptosis comprising msx1 or a gene encoding the same as an active ingredient |
| 01/21/2010 | US20100016221 Method of degrading protein by chaperone-mediated autophagy |
| 01/21/2010 | US20100016220 for diagnosis of a colorectal cell proliferative disease; treatment of gastric cancer or colorectal cancer |
| 01/21/2010 | US20100016219 Ophthalmic compositions containing solubilized cyclosporin |
| 01/21/2010 | US20100016218 Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders |
| 01/21/2010 | US20100016217 Derivatisation of granulocyte colony-stimulating factor |
| 01/21/2010 | US20100016216 Adiponectin and uses thereof |
| 01/21/2010 | US20100016215 Compound and method for treating myotonic dystrophy |
| 01/21/2010 | US20100016214 Carbohydrates mixture |
| 01/21/2010 | US20100016213 Use of a diterpenoid compound for treating diabetes |
| 01/21/2010 | US20100016212 Methods for treating pulmonary hypertension and compositions comprising vasoactive intestinal peptide |
| 01/21/2010 | US20100016211 Treatment of Melanoma With Alpha Thymosin Peptides |
| 01/21/2010 | US20100016210 Sensotherapy |
| 01/21/2010 | US20100016209 Methods of Reducing Side Effects in Cancer Therapy |
| 01/21/2010 | US20100016208 Photoactivatable antimicrobial agents |
| 01/21/2010 | US20100016207 Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid |
| 01/21/2010 | US20100015723 Antagonists of Interleukin-15 |
| 01/21/2010 | US20100015684 Factor vii: remodeling and glycoconjugation of factor vii |
| 01/21/2010 | US20100015240 Process for preparing microparticles containing bioactive peptides |
| 01/21/2010 | US20100015238 Powder Compositions for Inhalation |
| 01/21/2010 | US20100015235 Compositions and methods for treating multiple sclerosis |
| 01/21/2010 | US20100015230 Bone Morphogenetic Protein Compositions |
| 01/21/2010 | US20100015226 Bioresorbable hydrogel |